Literature DB >> 15308169

A new approach to determine tumor-to-blood 10B concentration ratios from the clinical outcome of a BNCT treatment.

S J González1, D G Carando, M R Bonomi.   

Abstract

A new approach to determine the tumor-to-blood (10)B concentration ratio in boron neutron capture therapy (BNCT) is introduced. It is a statistical method, which uses maximum likelihood estimation on the clinical outcome of a BNCT treatment. Its performance is shown in a clinical case of cutaneous multiple nodular melanomas. The calculations involve a detailed dosimetry analysis, the determination of tumor control probabilities for the different nodules, the maximum likelihood estimation itself, and a parametric bootstrap to obtain confidence intervals for the tumor-to-blood ratio. The obtained ratio is 3.05 +/- 0.46 with a 95%-confidence interval. These results are consistent with those found in literature. Moreover, a single patient with multiple nodules proves enough to get statistically relevant results. The proposed method does not involve surgery and can be performed after a BNCT treatment without being invasive for the patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308169     DOI: 10.1016/j.apradiso.2004.05.069

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  1 in total

1.  A Boronated Derivative of Temozolomide Showing Enhanced Efficacy in Boron Neutron Capture Therapy of Glioblastoma.

Authors:  Jing Xiang; Lin Ma; Zheng Gu; Hongjun Jin; Hongbin Zhai; Jianfei Tong; Tianjiao Liang; Juan Li; Qiushi Ren; Qi Liu
Journal:  Cells       Date:  2022-03-31       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.